Grail shares surge after FDA staff see no major test concerns
US FDA staff reviewers said they did not raise major concerns about the accuracy and safety of Grail’s multi-cancer blood test. Grail’s shares surged 35% on Monday.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.